NUCLEA BIOTECHNOLOGIES INC has a total of 41 patent applications. Its first patent ever was published in 2008. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, measurement and pharmaceuticals are CHENG SHULING, BEIJING JIUQIANG BIOTECHNOLOGY CO LTD and TOWNS KK.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 17 | |
#2 | EPO (European Patent Office) | 9 | |
#3 | WIPO (World Intellectual Property Organization) | 9 | |
#4 | Australia | 3 | |
#5 | Canada | 3 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Measurement | |
#3 | Pharmaceuticals | |
#4 | Electrical machinery and energy | |
#5 | Computer technology | |
#6 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Measuring microorganism processes | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Therapeutic chemical compounds | |
#6 | Medical preparations | |
#7 | Electric discharge tubes | |
#8 | Enzymes | |
#9 | Electric digital data processing | |
#10 | Bioinformatics |
# | Name | Total Patents |
---|---|---|
#1 | Muraca Patrick J | 41 |
#2 | Xu Ying | 5 |
#3 | Tam Sun W | 5 |
#4 | Zhang Yunhui | 2 |
#5 | Drescher Christopher S | 2 |
Publication | Filing date | Title |
---|---|---|
US2015309034A1 | Biomarker panel for prediction of recurrent colon cancer | |
WO2015026893A1 | Predictive biomarkers for metabolic syndrome | |
WO2015026909A2 | Msia-srm assay for biomarker analysis | |
US2014371087A1 | Mixed format microarrays | |
US2013338027A1 | Predictive Markers For Cancer and Metabolic Syndrome | |
US2015133342A1 | Mrm-ms signature assay | |
WO2013096534A1 | Congestive heart failure biomarkers | |
CA2852757A1 | Predictive biomarkers for breast cancer | |
WO2012142349A2 | Gene expression profile for therapeutic response to vegf inhibitors | |
EP2599793A1 | Anti-phospho-akt antibodies | |
US2009111124A1 | Kinase peptides and antibodies |